Diclofenamide

Diclofenamide

Skeletal formula of diclofenamide
Space-filling model of diclofenamide
Clinical data
AHFS/Drugs.com	International Drug Names
MedlinePlus	a601233
ATC code	S01EC02 (WHO)
Pharmacokinetic data
Protein binding	55%
Identifiers
IUPAC name 4,5-Dichlorobenzene-1,3-disulfonamide
CAS Number	120-97-8 checkY
PubChem CID	3038
IUPHAR/BPS	6807
DrugBank	DB01144 ☒N
ChemSpider	2930 checkY
UNII	VVJ6673MHY
KEGG	D00518 checkY
ChEBI	CHEBI:101085 checkY
ChEMBL	ChEMBL17 checkY
E number	{{#property:P628}}
CompTox Dashboard (EPA)	{{#property:P3117}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C6H6Cl2N2O4S2
Molar mass	305.14 g·mol−1
3D model (JSmol)	Interactive image
Melting point	228.5 °C (443.3 °F)
SMILES Clc1c(cc(cc1Cl)S(=O)(=O)N)S(=O)(=O)N
InChI InChI=1S/C6H6Cl2N2O4S2/c7-4-1-3(15(9,11)12)2-5(6(4)8)16(10,13)14/h1-2H,(H2,9,11,12)(H2,10,13,14) checkY Key:GJQPMPFPNINLKP-UHFFFAOYSA-N checkY
☒NcheckY (what is this?)  (verify)

Diclofenamide (or dichlorphenamide) is a sulfonamide and a carbonic anhydrase inhibitor of the meta-disulfamoylbenzene class. Dichlorphenamide as a carbonic anhydrase inhibitor is used for the treatment of acute angle closure glaucoma. While Dichlorphenamide does contain two sulfate groups within the structure, it falls under the class of a first generation carbonic anhydrase Inhibitor.

Uses

Diclofenamide was approved in the United States in 1958 as Daranide to treat glaucoma, Subsequently, it was found effective in cases of therapy-resistant epilepsy. In 2015, the medication was approved in the US under the name Keveyis as an orphan drug for the treatment of primary hypokalemic and hyperkalemic periodic paralysis.

Cost

In 2001, diclofenamide had a U.S. list price of $50 for a bottle of 100 pills, and was approved for glaucoma. Merck discontinued diclofenamide when better glaucoma drugs were developed. In 2010, Sun Pharmaceutical Industries bought the rights. In 2015, the F.D.A. approved it as an orphan drug, with 7-year exclusive marketing rights, for periodic paralysis, which the company estimates affects 5,000 people in the U.S. In 2016, Strongbridge Biopharma acquired Sun, which raised the price to $15,001 for 100 pills. The cost of treatment would range from $109,500 to $219,000 a year. Sun gives the drug free to patients who don't have insurance.